The European Pharmacopoeia (Ph. Eur.) is the official compendium of quality standards for medicines, their ingredients, and pharmaceutical preparations used throughout Europe. Published by the European Directorate for the Quality of Medicines & HealthCare (EDQM) under the Council of Europe, it is legally binding in 39 European countries. The current edition is the Ph. Eur. 12th Edition (launched June 2025). Ovalab performs pharmaceutical testing according to Ph. Eur. monographs.
Key Facts About the European Pharmacopoeia
- Current edition: Ph. Eur. 12th Edition (online-only from June 2025), replacing the annual supplement cycle with three issues per year (12.1, 12.2, 12.3).
- Legal basis: The Convention on the Elaboration of a European Pharmacopoeia (1964, Council of Europe) makes Ph. Eur. monographs legally binding standards in signatory states.
- Scope: Over 2,400 monographs covering active substances, excipients, dosage forms, vaccines, herbal drugs, and general methods of analysis.
- General chapters: Section 2 contains general methods including 2.2 (physical/physicochemical methods), 2.6 (biological tests), 2.9 (pharmaceutical-technical tests), and 5.4 (residual solvents).
- EU Directive 2001/83/EC: Requires that medicinal products comply with Ph. Eur. monographs where they exist. Marketing authorizations must reference Ph. Eur. standards for quality control.
Testing Methods at Ovalab
Ovalab performs pharmaceutical quality testing following Ph. Eur. monographs for API assay, related substances, dissolution, uniformity of dosage units, and microbiological examination. All methods are validated per ICH Q2(R1). Testing operates under GMP certification (SÚKL 74726/2023) and ISO/IEC 17025:2017 accreditation (ČIA 537/2025).
Frequently Asked Questions
What is the European Pharmacopoeia?
The Ph. Eur. is the official collection of quality standards for medicines in Europe, published by EDQM under the Council of Europe. It contains monographs specifying identity, purity, potency, and other quality requirements for drug substances, excipients, and dosage forms.
Is the Ph. Eur. legally binding?
Yes. The Ph. Eur. is legally binding in all 39 signatory states of the Council of Europe Convention. EU Directive 2001/83/EC requires that medicinal products comply with Ph. Eur. monographs where they exist.
What is the current edition?
The Ph. Eur. 12th Edition, launched in June 2025 as an online-only publication by EDQM. It replaced the 11th Edition and introduces a new annual cycle with three issues per year.
How does Ph. Eur. relate to USP and JP?
The Ph. Eur., USP (United States Pharmacopeia), and JP (Japanese Pharmacopoeia) are the three major pharmacopoeias. They collaborate through the Pharmacopoeial Discussion Group (PDG) to harmonize general methods and excipient monographs.
Does Ovalab test according to Ph. Eur. methods?
Yes. Ovalab follows Ph. Eur. monographs and general chapters for all pharmaceutical testing. Under GMP certification (SÚKL 74726/2023) and ISO/IEC 17025 accreditation, our results are accepted for batch release and regulatory submissions across the EU.